Hormone therapy and cardiovascular disease in the early postmenopause: The WHI data revisited

Climacteric

Volumn 10, Issue 3, 2007, Pages 195-196

  Pines, Amos ^a   Sturdee, David W ^a   Birkhäuser, Martin H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN;

AGING; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; DRUG EFFECT; HEART PROTECTION; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SHORT SURVEY;

AGE FACTORS; CARDIOVASCULAR DISEASES; CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; WOMEN'S HEALTH;

EID: 34248550755     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701401073     Document Type: Short Survey

References (5)

1. Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-12
3. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
4. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65
5. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77